The EGFR-TKI gefitinib, when administered to NSCLC patients carrying activating EGFR mutations (e.g., 15-bp deletion in exon 19, L858R in exon 21), significantly improved response and survival [1,2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.